乳腺癌血清TFF1水平及其在新辅助化疗疗效判定中的价值  

Serum TFF1 in Evaluating Efficacy of Neoadjuvant Chemotherapy for Patients with Breast Cancer

作　　者：马波 谢尚闹[1] 周娟娣[1] 王晓红[2] MA Bo;XIE Shang-nao;ZHOU Juan-di;WANG Xiao-hong(Zhejiang Hospital,Hangzhou 310013,China;Huzhou Center Hospital ,Huzhou 313000,China)

机构地区：[1]浙江医院,浙江杭州310013 [2]湖州市中心医院,浙江湖州313000

出　　处：《肿瘤学杂志》2018年第11期1080-1083,共4页Journal of Chinese Oncology

基　　金：浙江省医药卫生科技计划项目(2018255510);浙江省自然科学基金一般研究项目(LY18H040010)

摘　　要：[目的]探讨乳腺癌血清三叶因子1(TFF1)的表达及其在新辅助化疗疗效判定中的价值。[方法]采用ELISA方法检测血清TFF1在40例乳腺癌患者新辅助化疗前后、30例乳腺良性病患者(乳腺纤维腺瘤13例和乳腺囊性增生症17例)以及30例健康体检者外周血中的表达情况,并分析其与乳腺癌临床病理学特征间的关系;利用Medcal软件绘制血清TFF1降低值(△TFF1)评估化疗疗效的ROC曲线。[结果 ]血清TFF1水平乳腺癌组高于良性病组,两者均高于健康对照组(P<0.05)。完成新辅助化疗周期后,乳腺癌组患者血清TFF1水平下降(t=5.335,P<0.05);化疗后△TFF1判断化疗疗效的曲线下面积为0.753(95%CI:0.628-0.878),△TFF1最佳临界值为0.31ng/ml。化疗后不同疗效组患者血清TFF1水平比较差异有统计学意义(F=7.249,P<0.05)。[结论]血清TFF1在乳腺癌发生发展中可能发挥了重要作用,其在乳腺癌新辅助化疗疗效评估方面有着一定的意义。[Objective] To assess the application of serum trefoil factor 1(TFF1) in evaluating the efficacy of neoadjuvant chemotherapy for patients with breast cancer. [Methods] Serum TFF1 levels were measured by ELISA in 40 patients with breast cancer before and after neoadjuvant chemotherapy,and also measured in 30 patients with benign breast disease (13 cases of breast fibroadenoma and 17 cases of breast cystic hyperplasia)and 30 healthy controls. The ROC curve was applied to examine the role of serum TFF1 changes before and after chemotherapy(△TFF1)for evaluating the efficacy of chemotherapy. [Results] The levels of serum TFF1 in benign disease group and breast cancer group was higher than that in healthy control group,and the level of serum TFF1 in breast cancer group was higher than that in benign disease group(P<0.05). Serum TFF1 level in breast cancer patients after chemotherapy was significantly lower than that before chemotherapy(t=5.335,P<0.05). The area under the ROC curve of △TFF1 was 0.753(95%CI:0.628~0.878). The optimal cutoff value of △TFF1 was 0.31 ng/ml,there was significant difference in efficacy of chemotherapy between breast cancer patients with high and low △TFF1(F=7.249,P<0.05). [Conclusion] Serum TFF1 level may be used in evaluating the efficacy of neoadjuvant chemotherapy for patients with breast cancer.

关 键 词：乳腺癌 三叶因子1 新辅助化疗 评估 

分 类 号：R737.9[医药卫生—肿瘤]